2015 – Onxeo

Belinostat phase I/II results in soft tissue sarcoma to be presented at the 2015 Annual ASCO Meeting

04/09/201509/11/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Phase II trial results of Validive® presented at the ASCO Conference

04/02/201509/11/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Validive® at the MASCC/ISOO International Symposium: Oral presentation of Phase II trial results and meeting with its International Advisory Board

06/30/201509/06/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, has presented […]

Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma (PTCL)

11/09/201509/06/2019

Full results to be reported in Oral Presentation at 2015 ASH (American Society of Hematology) Annual Meeting Data demonstrate 89% […]

Meetings with the financial community during the 2nd semester of 2015

07/08/201509/06/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces its […]

Annual General Shareholders’ Meeting 2015: Results and convening to a new Meeting

04/15/201509/06/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhague : ONXEO), société innovante spécialisée dans le développement de médicaments orphelins en oncologie, informe ses […]

Combined Ordinary and Extraordinary General Meeting on April 15, 2015: Procedures for obtaining preparatory documents

03/25/201509/06/2019

Onxeo’s shareholders are invited to attend the Combined Ordinary and Extraordinary General Meeting to be held at 9:30am on April […]

Onxeo’s Combined General Meeting of Shareholders 2015

05/20/201509/06/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Onxeo announces evolution in the Board of Directors

10/06/201509/04/2019

Mr. Patrick Langlois is planning to step down from the chairmanship in early 2016 for personal reasons Mr. Joseph Zakrzewski […]

Onxeo to present at Biotech Showcase™ Annual Conference during JP Morgan Healthcare Conference – Onxeo repræsenteret ved Biotech Showcase™ Annual Conference under JP Morgan Healthcare Conference

01/08/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today […]

Onxeo announces its financial calendar for 2015

01/16/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today […]

Onxeo’s shares transferred to Compartment B on Euronext Paris

01/26/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today […]

Publication of a Shareholders Letter, January 2015

01/28/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today […]

Onxeo strengthens its executive management team

02/10/201509/04/2019

Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO), an innovative company specialised in orphan oncology treatments, has strengthened its […]

2014 Onxeo Review and 2015 Perspectives 2014 – Consolidated Financial Results

03/04/201509/04/2019

Successful strategic merger and acquisition of Danish company Topotarget giving birth to Onxeo Products’ major achievements: Beleodaq® approval in the […]

Judith Greciet, invited as guest speaker at international Allicense Conference May 5-6, 2015 – San Francisco, CA

03/31/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Publication of 2014 Reference Document and Annual Report

04/14/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Quarterly Information as of March 31, 2015

04/15/201509/04/2019

Significant advancements of company programs – Livatag®: Opening of new centres and active recruitment in the ReLive trial […]

Publication of a Letter to Shareholders – May 2015

05/12/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces […]

Onxeo meets US Investors during “French Life Sciences Days” event in New York on June 17 & 18, 2015

06/03/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced today […]

Onxeo Reports First Half 2015 Business Update and Consolidated Accounts

07/30/201509/04/2019

Livatag® Phase III trial in HCC: 50% of patients randomized Scientific recognition of Validive® and Beleodaq® preclinical and clinical data […]

Onxeo to present at InvestorDagen 2015

09/08/201509/04/2019

Onxeo to present at InvestorDagen 2015 The largest Danish private investor event September 22, 2015, Radisson Blu Scandinavia Hotel, Copenhagen […]

Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance” for the second consecutive year

09/17/201509/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has […]

Onxeo Validive® Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015

10/19/201509/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of […]

Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive® for Treatment of Severe Oral Mucositis

10/22/201509/04/2019

Results Presented in Oral ePoster Presentation at ASTRO Annual Meeting 2015 Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, […]

Onxeo to attend upcoming investor events

10/28/201509/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of […]

Onxeo Reports Third Quarter 2015 Business Update

11/05/201509/04/2019

Paris (France), Copenhagen (Denmark), November 5, 2015 – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today published an update on major milestones achieved during the third quarter of 2015 as well as its consolidated revenues for the period ending September 30, 2015. Avancée des programmes cliniques et position solide de trésorerie

Paris, (France), Copenhague, (Danemark), le 5 novembre 2015 – Onxeo SA (Euronext Paris, Nasdaq Copenhague – ONXEO), société innovante spécialisée dans le développement de médicaments orphelins en oncologie, annonce aujourd’hui les principales avancées opérationnelles et le chiffre d’affaires consolidé du 3ème trimestre 2015.

Onxeo initiates comprehensive strategy to extend value of key orphan oncology assets

11/18/201509/04/2019

Currently exploring combinations for synergistic effect to identify new indications for Livatag® and Beleodaq® Signed two collaborations with Lyon’s University […]

Spectrum Pharmaceuticals and Onxeo announce complete response in 67% of patients with peripheral T-cell lymphoma in combination of belinostat (Beleodaq®) and standard CHOP

12/06/201509/04/2019

Data was Highlighted in an Oral Presentation of a Phase 1 Study at the 57th Annual Meeting of the American […]

Onxeo announces its financial calendar for 2016

12/15/201509/04/2019

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of […]

Publication of shareholders’ letter

12/17/201509/04/2019

Paris (France), Copenhagen (Denmark)– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]

Onxeo Announces Preclinical & Clinical Data from Three Studies Supporting the Potential For Belinostat in Multiple Orphan Oncology Indications

04/09/201509/04/2019

Findings provide key validation; help identify target indications for optimal development Data demonstrating safety and efficacy to be presented at […]

Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC

10/05/201510/13/2018

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of […]

Publication of a new letter to shareholders

09/30/201510/13/2018

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of […]

Decision in the litigation opposing Onxeo to the companies Eurofins and ABL

09/22/201510/13/2018

Decision in the litigation opposing Onxeo to the companies Eurofins and ABL Recognition of Eurofins’s debt to Onxeo resulting from […]

Onxeo files application for key Livatag® patent

09/15/201510/12/2018

Potential expansion of Livatag IP estate to extend commercial exclusivity through 2036 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an […]

Update on ReLive, Livatag® international phase III clinical trial in HCC – 50% patients randomized

07/21/201510/12/2018

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, updates on […]

Beleodaq® (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology (JCO)

06/23/201510/12/2018

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Onxeo consolidates its industrial property with a US patent protecting Validive® until 2029

06/18/201510/12/2018

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced […]

Onxeo Announces Final Data from Completed Phase II Trial of Validive® for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients

05/26/201510/12/2018

Data confirm Validive® efficacy and safety; Provide basis for planned Phase 3 Trial Full results to be presented at ASCO […]